pfizer inc. - PFE

PFE

Close Chg Chg %
25.10 -0.16 -0.65%

Closed Market

24.94

-0.16 (0.65%)

Volume: 46.17M

Last Updated:

Nov 20, 2024, 3:59 PM EDT

Company Overview: pfizer inc. - PFE

PFE Key Data

Open

$25.06

Day Range

24.65 - 25.10

52 Week Range

24.48 - 31.54

Market Cap

$142.24B

Shares Outstanding

5.67B

Public Float

5.66B

Beta

0.65

Rev. Per Employee

N/A

P/E Ratio

33.74

EPS

$0.75

Yield

665.34%

Dividend

$0.42

EX-DIVIDEND DATE

Nov 8, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

50.20M

 

PFE Performance

1 Week
 
1.21%
 
1 Month
 
-14.10%
 
3 Months
 
-13.15%
 
1 Year
 
-17.70%
 
5 Years
 
-30.83%
 

PFE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About pfizer inc. - PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

PFE At a Glance

Pfizer Inc.
66 Hudson Boulevard East
New York, New York 10001-2192
Phone 1-212-733-2323 Revenue 58.50B
Industry Pharmaceuticals: Major Net Income 2.13B
Sector Health Technology Employees 88,000
Fiscal Year-end 12 / 2024
View SEC Filings

PFE Valuation

P/E Current 33.419
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 76.671
Price to Sales Ratio 2.81
Price to Book Ratio 1.826
Price to Cash Flow Ratio 18.892
Enterprise Value to EBITDA 21.566
Enterprise Value to Sales 3.88
Total Debt to Enterprise Value 0.331

PFE Efficiency

Revenue/Employee 664,727.273
Income Per Employee 24,238.636
Receivables Turnover 5.234
Total Asset Turnover 0.276

PFE Liquidity

Current Ratio 0.907
Quick Ratio 0.693
Cash Ratio 0.266

PFE Profitability

Gross Margin 50.06
Operating Margin 7.24
Pretax Margin 1.809
Net Margin 3.646
Return on Assets 1.007
Return on Equity 2.31
Return on Total Capital 1.30
Return on Invested Capital 1.50

PFE Capital Structure

Total Debt to Total Equity 84.302
Total Debt to Total Capital 45.741
Total Debt to Total Assets 33.131
Long-Term Debt to Equity 72.083
Long-Term Debt to Total Capital 39.111
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Pfizer Inc. - PFE

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
41.91B 81.29B 100.33B 58.50B
Sales Growth
-19.02% +93.97% +23.43% -41.70%
Cost of Goods Sold (COGS) incl D&A
12.06B 34.41B 38.24B 29.21B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.78B 5.19B 5.06B 6.29B
Depreciation
1.34B 1.49B 1.46B 1.56B
Amortization of Intangibles
3.44B 3.70B 3.61B 4.73B
COGS Growth
-18.14% +185.23% +11.12% -23.61%
Gross Income
29.84B 46.88B 62.09B 29.28B
Gross Income Growth
-19.37% +57.07% +32.46% -52.84%
Gross Profit Margin
+71.21% +57.67% +61.89% +50.06%
2020 2021 2022 2023 5-year trend
SG&A Expense
20.82B 26.08B 24.54B 25.05B
Research & Development
9.41B 13.83B 11.43B 10.58B
Other SG&A
11.42B 12.25B 13.12B 14.47B
SGA Growth
-9.04% +25.24% -5.91% +2.07%
Other Operating Expense
- - - -
-
Unusual Expense
1.67B (176.00M) 2.12B 7.47B
EBIT after Unusual Expense
7.35B 20.97B 35.43B (3.24B)
Non Operating Income/Expense
1.60B 4.63B 538.00M 6.51B
Non-Operating Interest Income
73.00M 36.00M 251.00M 1.62B
Equity in Earnings of Affiliates
298.00M 471.00M 436.00M 505.00M
Interest Expense
1.45B 1.29B 1.24B 2.21B
Interest Expense Growth
-7.94% -10.90% -4.11% +78.43%
Gross Interest Expense
1.54B 1.40B 1.36B 2.37B
Interest Capitalized
96.00M 108.00M 124.00M 160.00M
Pretax Income
7.50B 24.31B 34.73B 1.06B
Pretax Income Growth
-57.60% +224.28% +42.85% -96.95%
Pretax Margin
+17.89% +29.91% +34.61% +1.81%
Income Tax
476.00M 1.85B 3.33B (1.11B)
Income Tax - Current - Domestic
429.00M 3.38B 2.72B 1.19B
Income Tax - Current - Foreign
1.51B 2.77B 4.37B 1.14B
Income Tax - Deferred - Domestic
(1.18B) (4.34B) (3.58B) (2.79B)
Income Tax - Deferred - Foreign
(292.00M) 48.00M (183.00M) (652.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
298.00M 471.00M 436.00M 505.00M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
7.02B 22.46B 31.40B 2.17B
Minority Interest Expense
36.00M 45.00M 35.00M 39.00M
Net Income
6.99B 22.41B 31.37B 2.13B
Net Income Growth
-57.07% +220.90% +39.93% -93.20%
Net Margin Growth
+16.67% +27.57% +31.26% +3.65%
Extraordinaries & Discontinued Operations
- 2.63B (268.00M) (1.00M)
Discontinued Operations
- 2.63B (268.00M) (1.00M)
Net Income After Extraordinaries
9.62B 22.15B 31.36B 2.13B
Preferred Dividends
- - - -
-
Net Income Available to Common
9.62B 22.15B 31.36B 2.13B
EPS (Basic)
1.731 3.9539 5.5929 0.3755
EPS (Basic) Growth
-40.76% +128.42% +41.45% -93.29%
Basic Shares Outstanding
5.55B 5.60B 5.61B 5.64B
EPS (Diluted)
1.7074 3.8798 5.471 0.3755
EPS (Diluted) Growth
-40.46% +127.23% +41.01% -93.14%
Diluted Shares Outstanding
5.63B 5.71B 5.73B 5.71B
EBITDA
13.79B 25.98B 42.61B 10.53B
EBITDA Growth
-31.46% +88.36% +64.00% -75.30%
EBITDA Margin
+32.92% +31.97% +42.47% +17.99%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 32.60
Number of Ratings 27 Current Quarters Estimate 0.481
FY Report Date 12 / 2024 Current Year's Estimate 2.893
Last Quarter’s Earnings 1.06 Median PE on CY Estimate N/A
Year Ago Earnings 1.84 Next Fiscal Year Estimate 2.893
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 16 4 22 22
Mean Estimate 0.48 0.75 2.89 2.89
High Estimates 0.69 0.80 3.13 3.30
Low Estimate 0.27 0.66 2.50 2.43
Coefficient of Variance 22.59 8.88 4.93 7.89

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 9 9
OVERWEIGHT 2 2 1
HOLD 14 15 14
UNDERWEIGHT 0 0 0
SELL 1 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Pfizer Inc. - PFE

Date Name Shares Transaction Value
Jul 17, 2024 Jennifer B. Damico SVP & Controller 28,794 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 17, 2024 Albert Bourla Chairman & CEO; Director 669,258 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 17, 2024 Rady A. Johnson Executive Vice President 8,993 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2024 David M. Denton Chief Financial Officer & EVP 37,919 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $28.66 per share 1,086,758.54
Apr 29, 2024 Shantanu Narayen Director 142,518 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 29, 2024 James C. Smith Director 128,556 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 29, 2024 Scott Gottlieb Director 34,886 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 29, 2024 Suzanne Nora Johnson Director 100,297 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 29, 2024 Susan J. Hockfield Director 31,188 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 29, 2024 Susan D. Desmond-Hellmann Director 28,356 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 29, 2024 Ronald Edward Blaylock Director 58,627 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 29, 2024 Helen H. Hobbs Director 113,061 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 29, 2024 James Quincey Director 48,496 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 29, 2024 Joseph J. Echevarria Director 113,236 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 29, 2024 Dan R. Littman Director 50,295 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 29, 2024 Lidia L. Fonseca Executive Vice President 68,045 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 29, 2024 Lidia L. Fonseca Executive Vice President 60,124 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 29, 2024 Douglas M. Lankler Executive Vice President 110,756 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 29, 2024 Douglas M. Lankler Executive Vice President 125,347 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 29, 2024 Sally Susman Executive Vice President 68,045 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Pfizer Inc. in the News